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Although protein-misfolding-mediated neurodegen-
erative diseases have been linked to aging, how
aging contributes to selective neurodegeneration
remains unclear. We established spinocerebellar
ataxia 17 (SCA17) knockin mice that inducibly ex-
press one copy of mutant TATA box binding protein
(TBP) at different ages by tamoxifen-mediated Cre
recombination. We find that more mutant TBP accu-
mulates in older mouse and that this accumulation
correlates with age-related decreases in Hsc70 and
chaperone activity. Consistently, older SCA17 mice
experienced earlier neurological symptom onset
and more severe Purkinje cell degeneration. Mutant
TBP shows decreased association with XBP1s, re-
sulting in the reduced transcription ofmesencephalic
astrocyte-derived neurotrophic factor (MANF), which
is enriched in Purkinje cells. Expression of Hsc70
improves the TBP-XBP1s interaction andMANF tran-
scription, and overexpression of MANF ameliorates
mutant TBP-mediated Purkinje cell degeneration
via protein kinase C (PKC)-dependent signaling.
These findings suggest that the age-related decline
in chaperone activity affects polyglutamine protein
function that is important for the viability of specific
types of neurons.
INTRODUCTION
Aging is a complex biological process and a known primary risk
factor for neurodegenerative diseases caused by protein
misfolding, such as Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, and other polyglutamine (polyQ)-expan-
sion-mediated diseases that frequently occur in the middle or
late stages of life. The misfolded proteins are known to accumu-
late with age in neuronal cells, and this accumulation increases
the level of toxic forms of proteins that can induce neurodegen-
eration. Aging is also linked to several pathological pathways,
including mitochondria dysfunction (Passos and von Zglinicki,2005), reactive oxygen species damage (Afanas’ev, 2010), and
protein homeostasis disturbance (Akerfelt et al., 2010), which
are implicated in neurodegenerative diseases.
Given that neurons are terminally differentiated cells that do
not divide, it remains unclear whether aging-related factors
promote the accumulation of mutant proteins in neurons versus
the greater length of time proteins are expressed or whether
aged neurons are more vulnerable to misfolded proteins versus
the cumulative effects of misfolded proteins with age. Under-
standing the mechanisms underlying age-dependent neurode-
generation is critical if we are to develop effective therapeutics
for protein-misfolding-mediated neurodegenerative diseases.
For example, if aged neurons are more vulnerable to misfolded
proteins than young neurons, then reversing aging-related
cellular dysfunction would be more effective than reducing the
expression of polyQ proteins in treating these neurodegenerative
diseases, especially given that proteins with expanded polyQ
repeats may still preserve critical function (Cattaneo et al., 2005).
Unfortunately, sorting out these important issues is difficult
using current genetic mouse models of neurodegenerative dis-
eases. This is because most of these mouse models express
mutant proteins throughout life, making it difficult to distinguish
between the cumulative effects of mutant proteins on neuronal
cells over time versus a greater vulnerability of aged neurons to
mutant proteins. To remedy this, we established an inducible
mouse model of spinocerebellar ataxia 17 (SCA17) that allows
for the expression of mutant proteins at different ages, enabling
us to examine whether and how aged neurons are particularly
affected. SCA17 is caused by polyQ expansion in the TATA
box binding protein (TBP), a transcription factor essential for
the expression of most genes. Despite the critical function of
TBP, in SCA17 patients, expansion of the polyQ (>42 glutamines)
in TBP results in late-onset neurological symptoms, including
ataxia, rigidity, dystonia, and dementia (Bruni et al., 2004; Rolfs
et al., 2003; Toyoshima et al., 2004); this polyQ expansion also
causes age-dependent neurodegeneration in the same manner
as the other eight polyQ diseases, among them Huntington’s
disease (Orr and Zoghbi, 2007). These facts suggest that the
neuronal toxicity ofmutant TBP and other polyQ disease proteins
depends on aging-related factors. Because TBP is a well-char-
acterized transcription factor, SCA17 makes an ideal model for
investigating how polyQ-expansion-mediated protein misfolding
causes neuronal degeneration in an age-dependent manner.Neuron 81, 349–365, January 22, 2014 ª2014 Elsevier Inc. 349
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MANF Decrease and Selective Neuropathology in SCA17Using our SCA17 knockin (KI) mouse model, we induced
mutant TBP expression in mice at different ages. We found
that SCA17 disease phenotypes in older mice progress much
faster, along with decreases in chaperone activity and Hsc70
level. In addition, mesencephalic astrocyte-derived neurotrophic
factor (MANF), a protein with a neuroprotective effect, is down-
regulated in the cerebellum, especially in the Purkinje cell layer,
in the presence of mutant TBP. Mutant TBP binds weakly to the
transcription factor XBP1s and mediates less MANF transcrip-
tion, which can be reversed by Hsc70 overexpression. Overex-
pression of MANF by lentiviral vector infection and transgenic
mouse approach ameliorates toxicity caused by mutant TBP in
Purkinje cells in SCA17 mice. MANF upregulates protein kinase
C (PKC) phosphorylation and reverses reduced PKC phosphor-
ylation in the cerebellum of SCA17 mice. These findings indicate
that age-related decrease in chaperone function could cause the
accumulation of mutant TBP and reduce its normal function on
MANF transcription, contributing to the selective neurodegener-
ation in SCA17.
RESULTS
Generation of Inducible SCA17 KI Mice
Wepreviously established floxed TBP105Qmice in which a tran-
scription stop codon is used to prevent the transcription of
mutant TBP (Huang et al., 2011) (Figure 1A). To induce the
expression of mutant TBP in mice at different ages, we crossed
floxed heterozygous TBP105Qmice with CreER transgenic mice
that express a fusion protein containing Cre recombinase and an
estrogen receptor ligand binding site under the control of
chicken b-actin promoter. Upon intraperitoneal injection of
tamoxifen, an estrogen receptor ligand, this ligand can bind
Cre recombinase fusion protein and cause it to enter the nucleus
and act on the loxP sites, resulting in the removal of the stop
codon and the expression of mutant TBP (Figure 1A). For
simplicity, the mice carrying both the floxed TBP105Q gene
and CreER transgene are referred to as TBP105Q inducible KI
mice. Littermates with other genotypes, including CreER trans-
genic mice, heterozygous TBP105Q floxed mice, and wild-type
(WT) mice, were used as control mice, given that the injection
of tamoxifen in these mice does not lead to the expression of
mutant TBP. Thus, tamoxifen can be injected into KI mice at
different ages in order to permanently induce mutant TBP
expression throughout the body.Figure 1. Characterization of TBP105Q Inducible KI Mouse Model
(A) A schematic illustration of expression of mutant TBP in TBP105Q inducible K
(B)Western blotting analysis of immunoprecipitated TBP from the cortex and liver
The rabbit polyclonal antibody EM192 was used to immunoprecipitate TBP, and t
(C) Mutant TBP aggregates in the stacking gel were clearly detected in the corte
anti-TBP (1TBP18) but not in the kidney (Kid).
(D) 1C2 immunohistochemical study confirming mutant TBP expression in the ce
injectedwith tamoxifen. Small aggregates of mutant TBPwere visualized in the nu
5 mm (right).
(E) TBP105Q inducible KI and control mice at 3, 9, or 14months of age were inject
mice showed earlier onset of body weight loss (day 35 for 14 months, p = 0.037
3 months, p = 0.0438) after tamoxifen injection (n = 9–11 each group, two-way A
(F) The body weight of differently aged KI mice was also compared.
(G) Representative images of differently aged (3, 9, and 14 months) KI mice (whiFirst, we injected tamoxifen in 3-month-old TBP105Q induc-
ible KI mice for 5 consecutive days. Different tissues were
collected for western blot analysis 2 months after the last injec-
tion. Soluble mutant TBP in the cortex and liver of injected KI
mice was seen in western blots probedwith 1C2 antibody, which
recognizes the expanded polyQ region. Immunoprecipitation of
mouse TBP with the rabbit polyclonal antibody EM192 verified
the existence of soluble mutant TBP in the cortex and liver (Fig-
ure 1B). Western blot probed with 1TBP18 antibody, which pref-
erentially reacts with aggregated forms of mutant TBP, revealed
SDS-insoluble mutant TBP aggregates in the stacking gel, which
were from the cerebellum, cortex, and muscle of KI mice (Fig-
ure 1C). Immunohistochemistry with 1C2 antibody also verified
the presence of mutant TBP in different brain regions in KI
mice 2 months after tamoxifen injection at the ages of 3 or
14 months. Nuclear staining of mutant TBP was evident in the
cortex, striatum, hippocampus, and cerebellum of these KI
mice (Figure 1D, left). Staining with 1TBP18 antibody revealed
small mutant TBP aggregates in the nucleus under high magnifi-
cation (1003) (Figure 1D, right). All these results confirm that
tamoxifen injection can induce the expression of mutant TBP
in the brain and peripheral tissues at different ages.
Aging Exacerbates Neurological Phenotypes and
Purkinje Neuron Degeneration in TBP105Q Inducible KI
Mice
To study the impact of agingonSCA17diseaseprogression in our
TBP105Q inducible KI mouse model, KI mice at 3, 9, and
14 months of age were injected with tamoxifen for 5 days and
then examined on aweekly basis for 3months or until death. After
tamoxifen injection, KI mice gradually developed characteristic
SCA17 disease phenotypes, such as reduced body weight,
impairedmotor function, andhunched-backappearance (Figures
1E–1G). Some14-month-oldmicedied starting from40daysafter
tamoxifen injection, but none of the 3-month-oldmice diedwithin
3months after injection. Because somemice had been sacrificed
in order to examine brain pathology and TBP expression at
different times after injection, the loss of body weight of these
mice was used to reflect disease severity, given that body weight
can also bemore reliably quantified than other behavioral pheno-
types. In comparison to the age-matched controls, older KI mice
displayed a significant loss of body weight at an earlier time after
tamoxifen-induced expression of mutant TBP; for example, 14-
month-old KI mice started to lose their body weight significantlyI mice.
ofWT and TBP105Q inducible KImice after tamoxifen induction for twomonths.
he mouse monoclonal antibody 1C2 was used to visualize mutant TBP (arrow).
x (Ctx), cerebellum (Cere), and muscle (Mus) of TBP105Q inducible KI mice by
rebellum, hippocampus, cortex, and striatum of 3- and 14-month-old KI mice
cleus under 1003magnification (arrows). Scale bars represent 100 mm (left) and
ed with tamoxifen in order to induce the expression of mutant TBP. The older KI
4) than the younger KI mice (day 53 for 9 months, p = 0.0125, and day 113 for
NOVA, p < 0.0001).
te arrow) were taken at the indicated days after tamoxifen injection.
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mice showed a significant weight loss at 53 days after injection.
On the other hand, 3-month-old KI mice showed no obvious
body weight reduction until 113 days after injection (Figure 1E).
Comparing KI mice at different ages also showed that older KI
mice lost more body weight than younger KI mice (Fig-
ure 1F). Consistently, a hunched-back appearance of 3-, 9-,
and 14-month-old KI mice was seen at 130, 75, and 60 days after
tamoxifen injection, respectively (Figure 1G). We also analyzed
rotarod performance to measure the motor function of KI mice.
In agreement with the loss of body weight result, 14-month-old
KI mice had the worst performance, given that the time they
stayed on a rotating rod was significantly shorter than the age-
matched controls, and this motor function deficiency started
earlier (day 9 after tamoxifen injection) than in 3- and 9-month-
old KI mice (day 15 after injection) (Figure 2A). The oldest KI
mice (14 months old) also had poorer rotarod performance than
the younger (3- and 9-month-old) KI mice (Figure 2B). To further
characterize the motor deficit, 1.5 months after tamoxifen injec-
tion, KI mice at different ages were subjected to balance beam
assay. The performance of 3-month-old KImicewas comparable
to age-matched controls, whereas 14-month-old KI mice took a
significantly longer time to walk through the beam, suggesting
an age-related decline in motor coordination and activity (Fig-
ure 2C). Ataxia is a definitive phenotype of SCA17 and results in
gait abnormality. Using a foot-printing assay, we found that gait
abnormality was most apparent in 14-month-old KI mice
(Figure S1A available online), given that the stride length of
14-month-old KI micewas significantly decreased in comparison
to 3- and 9-month-old KI mice (Figures S1A and S1B).
Next, we wanted to correlate the phenotypes observed in KI
mice with Purkinje neuron degeneration, a characteristic neuro-
pathological feature seen in both SCA17 patients (Rolfs et al.,
2003) and previously established SCA17 mouse models
(Friedman et al., 2007; Huang et al., 2011). In comparison to
16-month-old WT mice, immunostaining with an antibody to
calbindin, a specific marker protein for Purkinje cells, revealed
that the 14-month-old KI mice had the most severe Purkinje
neuron loss after 2 months of tamoxifen injection, given that
the molecular layer thickness and dendritic branches were also
significantly decreased; the 9-month-old KI mice had a modest
level of degeneration, whereas the Purkinje neurons in the
3-month-old group remained largely intact (Figures 2D, 2E, and
S1C). Furthermore, these results were confirmed by conven-
tional Nissl and Golgi staining (Figures S1D and S1E). Western
blot analysis of the ratio of calbindin to actin in the cerebellum
of KI mice at different ages also verified that the older KI mice
showed greater loss of Purkinje cells after turning on the expres-
sion of mutant TBP by tamoxifen injection (Figures 2F and 2G).
Because the tamoxifen induction time was the same for KI
mice at different ages, all these results unequivocally suggest
that aging accelerates the disease progression and neurodegen-
eration in our SCA17 KI mouse model.
Aging Promotes Mutant TBP Accumulation in TBP105Q
Inducible KI Mice
In order to assess whether aging influences the expression levels
of mutant TBP, we used western blots to examine the levels of352 Neuron 81, 349–365, January 22, 2014 ª2014 Elsevier Inc.SDS soluble mutant TBP, because mounting evidence suggests
that, in polyQ disease models, soluble mutant protein is more
pathogenic than aggregated proteins (Nagai et al., 2007; Taka-
hashi et al., 2008). There were higher levels of mutant TBP in
the cortex and the cerebellum of 9- and 14-month-old KI mice
than 3-month-old KI mice 3 months after tamoxifen induction
(Figures 3A and 3B). However, semiquantitative RT-PCR
showed similar amounts of mutant TBP transcripts in 3- and
9-month-old KI mice after tamoxifen injection (Figures 3C and
3D), suggesting that mutant TBP tends to accumulate in aged
neurons at the protein level. Consistent with our previous trans-
genic mouse model (Friedman et al., 2007), there is a reduced
amount of WT TBP protein in the presence of mutant TBP (Fig-
ures 3E and 3F). To rule out the possibility that the reduced WT
TBP protein is due to only one functional allele of WT TBP in KI
mice, we compared WT TBP level in KI mice with or without
tamoxifen injection. WT TBP was only decreased when mutant
TBP was induced after KI mice were injected with tamoxifen
(Figure S1F), suggesting that the total amount of TBP is tightly
regulated and that the expression of mutant TBP can down-
regulate WT TBP, presumably because of the critical functions
of TBP.
Aging Decreases Chaperone Activity and Hsc70 Levels
in Mouse Brain
There are three major cellular mechanisms for coping with mis-
folded proteins accumulated in the brain: the chaperone system,
the ubiquitin-proteasome system (UPS), and the autophagy sys-
tem (Gestwicki and Garza, 2012; Li and Li, 2011). Several studies
already implicate aging in impaired UPS activity in the CNS
(Keller et al., 2000), but whether aging affects autophagy and
chaperone function remains to be fully investigated. First, we
checked autophagy activity in the cortex and cerebellum of 3-,
12-, and 21-month-old WT mice by measuring the level of
LC3B, a component of autophagosomes, and p62/SQSTM1, a
polyubiquitin binding protein degraded by autophagy. We saw
no detectable differences of either LC3B or p62 between
different ages (Figure 4A), suggesting that autophagy activity in
the brain is not significantly impacted by aging, at least under un-
stressed conditions.
Next, we focused on the chaperone system, which consists
of a large family of proteins. To measure chaperone, we adop-
ted an in vitro luciferase protection assay activity (Thulasiraman
and Matts, 1998) in which brain lysate and recombinant lucif-
erase were mixed together and incubated at a denaturing tem-
perature (42C). At this temperature, the luciferase is thermally
unstable and tends to misfold, whereas the chaperones in the
brain lysates can prevent misfolding and maintain the lucif-
erase activity. With chaperone inhibitor PU-H71 added into
the mixture as a control, the specific chaperone activity could
be quantified (Figure 4B). We found that the luciferase activity
significantly decreased with the lysates from aged cortex and
cerebellum (Figure 4C), supporting the idea that chaperone
activity declines during aging. Furthermore, we explored which
members of the chaperones were responsible for this change.
By individually checking each form of the major chaperones
with western blot analysis, we found that the protein levels
of Hsc70 and Hsp90 were significantly decreased in the
Figure 2. Aging Exacerbates Neurological Phenotypes in TBP105Q Inducible KI Mouse Model
(A) Motor activity of mice injected with tamoxifen at 3, 9, and 14 months of age was analyzed by rotarod test. The older KI mice (day 9 for 14 months, p = 0.0031)
showed earlier onset ofmotor impairment than the younger KImice (day 15 for 9months, p = 0.0298, and day 15 for 3months, p = 0.0217) after tamoxifen injection
(n = 9–11 each group, two-way ANOVA, p < 0.0001).
(B) The rotarod performance of differently aged KI mice was also compared.
(C) Motor coordination of mice was tested by balance beam walking assay 1.5 months after tamoxifen injection. The walking time of older TBP105Q inducible KI
mice on the beam is significantly longer than that of young KI mice (n = 6; **p < 0.01).
(D) Degeneration of Purkinje neurons labeled by anticalbindin in the cerebellum of KImice injectedwith tamoxifen at different ages.WTmouse at 16months of age
served as a control. The scale bar represents 50 mm.
(E) Quantification of Purkinje neuron number, molecular layer thickness, and dendritic branches in TBP105Q inducible KI mice at different ages (n = 6–8; *p < 0.05,
**p < 0.01).
(F and G) Western blotting (F) and quantitative analysis (G) of calbindin protein level in the cerebellum of 3-, 9-, and 14-month-old TBP105Q inducible KI mice.
Actin was used as a loading control (*p < 0.05, **p < 0.01). Data are represented as mean ± SEM.
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Figure 3. Age-Related Increase of Mutant TBP and Decrease of Wild-Type TBP in TBP105Q Inducible KI Mice
(A) Western blotting analysis of soluble mutant TBP levels in the cortex and cerebellum of 3-, 9-, and 14-month old TBP105Q inducible KI mice. An age-related
increase of soluble mutant TBP (arrow) was observed in KI mice. Control mice (Con) did not show mutant TBP expression. Actin was used as a loading control.
(B) Quantification of the relative amount of TBP (the ratio of TBP to actin) on western blots (*p < 0.05).
(C) RT-PCR revealed similar mRNA levels of mutant TBP in both the cortex and cerebellum of 3- and 9-month-old TBP105Q inducible KI mice. Actin was used as
an internal control.
(D) The ratio of mutant TBP to actin transcripts in RT-PCR is quantified.
(E) Western blotting analysis of the expression of mouse endogenous WT TBP in the cerebellum of TBP105Q inducible KI and WT mice at 3, 9, and 14 months
of age.
(F) Quantitative analysis of WT TBP level on western blots by measurement of its ratio to actin (*p < 0.05, **p < 0.01). Data are represented as mean ± SEM.
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and Hsp40 levels remained stable (Figures 4D and 4E). Immu-
nohistochemistry confirmed that Hsc70 level was reduced in
the Purkinje cells of 18- and 24-month-old WT mice in com-354 Neuron 81, 349–365, January 22, 2014 ª2014 Elsevier Inc.parison to 6-month-old WT mice (Figure 4F). Therefore, the
age-related reduction of Hsc70 could explain the weakened
luciferase protection and is also likely to accelerate mutant
TBP accumulation in aged TBP105Q inducible KI mice.
Figure 4. Age-Dependent Decrease in Chaperone Activity and Hsc70 Level in Mouse Brain
(A) Western blotting analysis of p62 and LC3B level in the cortex and cerebellum of 3-, 12-, and 21-month-old WT mice. No significant difference was found
among three age groups.
(B) Luciferase protection assay was performed by incubating recombinant luciferase with lysates from either the cortex or cerebellum of 3-, 12-, and 21-month-
old WT mice. Hsp inhibitor PU-H71 was added to the incubation in order to obtain Hsp-specific activity.
(C) Decreased luciferase intensity was observed when brain lysates of 12- or 21-month-old mice were used, indicating an age-related decrease of chaperone
activity in the cortex and cerebellum (*p < 0.05, **p < 0.01).
(D) Western blot analysis of major chaperones with the cerebellum tissue from 3-, 12-, and 21-month-old WT mice. Actin was used as a loading control.
(E) The relative levels of Hsp were normalized by actin for quantification. Hsc70 and Hsp90 showed a significant decrease with aging (*p < 0.05, **p < 0.01).
(F) Hsc70 immunostaining showing age-dependent decrease in Hsc70 expression in Purkinje cells in WT mice at different ages (6, 18, and 24 months). Arrows
indicate Purkinje cells. The scale bar represents 20 mm. Data are represented as mean ± SEM.
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MANF Decrease and Selective Neuropathology in SCA17Age-Related Decrease of Mesencephalic Astrocyte-
Derived Neurotrophic Factor Specifically Occurs in the
Cerebellum of TBP105Q Inducible KI Mice
Mutant TBP in aged neurons can selectively affect the expres-
sion of certain neuronal proteins to cause selective neurodegen-
eration. To identify such targets, we examinedmicroarray results
obtained previously with the cerebellum tissues from our TBP
transgenic mice (Friedman et al., 2007). One interesting candi-
date is MANF, which is alternatively named arginine-rich,
mutated in early-stage tumor (ARMET). Emerging evidence
argues that MANF plays a potential protective role on neuronal
survival (Hellman et al., 2011; Mizobuchi et al., 2007; Voutilainen
et al., 2009). Interestingly, we found that MANF was significantly
decreased in the cerebellum from 9- and 14-month-old KI mice,
which is consistent with increased mutant TBP with age after
tamoxifen injection (Figures 5A and 5B). We also checked
another neurotrophic factor, BDNF, but found that its level was
comparable to WT and KI mice (Figures S2A and S2B). These
results suggest that MANF is selectively reduced by mutant
TBP. Immunohistochemistry showed that MANF was enriched
in the Purkinje cell layer and was lost in 14-month-old KI mice
(Figure 5C). However, MANF staining intensity in other brain
regions, including the cortex, striatum, and brain stem, was
indistinguishable between WT and 14-month-old KI mice (Fig-
ure S2C). We performed the same immunostaining of a 12-
month-old HdhQ150 KI mouse and saw a clear enrichment of
MANF in the Purkinje cell layer (Figure S2D). All these findings
indicate that mutant TBP can specifically downregulate MANF
in Purkinje cells.
To investigate whether mutant TBP affects the transcription of
MANF, we performed semiquantitative PCR. We saw a
decreased level of MANF transcripts in the cerebellum of KI
mice in which mutant TBP was induced at 9 months of age,
but no such decrease was observed in the cortex or cerebellum
of KI mice that started to express mutant TBP at 3 months (Fig-
ure 5D); the decrease was further verified by quantitative PCR
via a real-time PCR assay (Figure 5E). On the basis of these re-
sults, we conclude that an age-related and tissue-specific
reduction of MANF mRNA underlies the decrease of its protein
expression.
Expanded polyQ Disrupts the Interaction between TBP
and XBP1s and Impairs the Transcription of MANF
Given that theMANFmRNA level is decreased in the presence of
mutant TBP, we reasoned that mutant TBP could impair MANF
transcriptional activity. However, no TATA box sequence is pre-
sent in the MANF promoter region, indicating that TBP regulates
MANF transcription via other transcription factors. An endo-
plasmic reticulum (ER) stress response element (ERSE) located
around 150 bp upstream of the MANF transcription initiation
site is known to play a critical role in regulating MANF transcrip-
tion and is recognized by XBP1 (Mizobuchi et al., 2007), a
transcription factor that is activated during ER stress and upre-
gulates genes important for protein folding, maturation, and
degradation (Lee et al., 2003). The activation of XBP1 involves
an unconventional mechanism: an ER transmembrane kinase,
IRE1, splices a 26 nt intron from XBP1mRNA. This splicing event
leads to a frameshift, which converts the biologically inactive356 Neuron 81, 349–365, January 22, 2014 ª2014 Elsevier Inc.XBP1u (unspliced) to its active form, XBP1s (spliced) (Yoshida
et al., 2001).
We hypothesized that mutant TBP affects XBP1s-mediated
MANF expression in aged neurons. Although we have found
that Hsc70 and Hsp90 decrease in the aged brain, Hsc70 has
been reported to maintain the protein-DNA binding complex
for gene transcription (Gehring, 2004; Li et al., 2008; Zeiner
et al., 1999). Thus, we wanted to compare the effects of normal
and mutant TBP on the binding of XBP1s to the MANF promoter
and also to know whether Hsc70 can influence this binding. To
explore this, we needed to use cultured cells in order to express
different TBP and Hsc70. First, we performed chromatin
immunoprecipitation (ChIP) of human embryonic kidney 293
(HEK293) cells that were transfected with XBP1s and TBP (either
13Q or 105Q) constructs (Figure 6A). Anti-FLAG was used to pull
down FLAG-tagged XBP1s. DNA was recovered from the pull-
down lysates and used as a template for semiquantitative PCR
of the MANF promoter. In comparison to TBP13Q, TBP105Q
significantly reduced the association of the MANF promoter
with XBP1s (Figure 6B).
Earlier literature indicates that TBP and XBP1s are present in
the same transcriptional complex (Hetz, 2012). We wanted to
know whether mutant TBP shows altered association with
XBP1s, which may account for the decreased association of
XBP1swith theMANF promoter andwhether Hsc70 can improve
the function of mutant TBP. To this end, HEK293 cells were
transfected with XBP1s and TBP (either 13Q or 105Q) in the
absence or presence of Hsc70. Then, transfected XBP1s was
precipitated with anti-XBP1. Significantly less TBP105Q than
TBP13Q was coprecipitated with XBP1s (Figure 6C), suggesting
that polyQ expansion impairs the interaction between TBP and
XBP1s. Furthermore, overexpression of Hsc70 greatly increased
the level of both TBP13Q and TBP105Q pulled down, indicating
that Hsc70 facilitates the association between TBP and XBP1s
(Figures 6C and 6D).
To functionally assess the effect of mutant TBP on the tran-
scription of MANF, we generated a luciferase reporter that is
expressed under the control of the MANF promoter (300,
+2 nt). As a negative control, we also made a mutant promoter
by deleting ERSE in the promoter (Figure 6E, top). HEK293 cells
were transfected with the MANF reporter in combination with
other constructs, and luciferase intensity was measured in order
to quantify MANF transcription levels. As expected, the overex-
pression of XBP1s, rather than XBP1u, dramatically increased
luciferase intensity, indicating that XBP1s indeed stimulates
MANF transcription (Figure 6E, bottom). Then, we compared
the reporter activity when TBP13Q or TBP105Q was presented
with XBP1s. Western blotting was used to quantify the expres-
sion level of the transfected proteins (Figure 6F). We found that
the expression of TBP105Q yielded a lower level of transcription
activity, which is consistent with its weaker association
with XBP1s. Importantly, coexpression of Hsc70 significantly
increased the reporter activity and eliminated the difference
between TBP13Q and TBP105Q (Figure 6G).
To examine whether overexpression of Hsc70 can upregulate
MANF expression, we used our previously generated PC12 cell
lines that stably express either TBP13Q or TBP105Q (Shah
et al., 2009). We found that the endogenous level of MANF was
Figure 5. Decreased MANF Level in Purkinje Neurons of TBP105Q Inducible KI Mice
(A) Western blotting analysis of MANF protein level in the cortex and cerebellum of 3-, 9-, and 14-month-old control and TBP105Q inducible KI mice.
(B) Quantification of the ratio of MANF to actin showing that only the cerebellum in TBP105Q inducible KI mice, starting at 9 months, had a significant decrease of
MANF in comparison to the control cerebellum (*p < 0.05, **p < 0.01).
(C) Immunohistochemical study showing the enrichment of MANF in Purkinje neurons of WT cerebellum, and this enrichment is lost in the cerebellum of
14-month-old TBP105Q inducible KI mouse. Scale bars represent 40 mm.
(D) RT-PCR revealed a decrease inMANFmRNA level, which is specific to the cerebellum of KImice at an old age (9months). Actinwas used as an internal control.
(E) Real-time PCR was used to confirm the RT-PCR result. Relative abundance of MANF was calculated with the value from the control mice set to 1, and actin
served as an internal control (*p < 0.05). Data are represented as mean ± SEM.
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Figure 6. Expanded polyQ Impairs the Binding of TBP with XBP1s and Its Transcriptional Activity for MANF Expression
(A) Western blotting analysis confirmed the expression of respective proteins (TBP13Q, TBP105Q, and XBP1s) in cells used for ChIP assay.
(B) Semiquantitative PCR result using lysates from chromatin immunoprecipitation with anti-FLAG (ChIP, left). Control was beads only without anti-FLAG. More
MANF promoter was pulled down in cells transfected with TBP13Q than with TBP105Q (right, **p < 0.01).
(C) Coimmunoprecipitation of transfected XBP1s with TBP in the presence or absence of Hsc70. XBP1s was pulled down by XBP1 antibody in each sample, and
less TBP105Q was pulled down with XBP1s. Overexpression of Hsc70 increased the precipitated amount of TBP (both 13Q and 105Q).
(legend continued on next page)
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MANF Decrease and Selective Neuropathology in SCA17decreased in TBP105Q cells. However, transfection of Hsc70
resulted in a significant increase in MANF level (Figure 6H). Simi-
larly, the TBP105Q cell line showed impaired neurite outgrowth
in response to nerve growth factor (NGF), but Hsc70 overexpres-
sion could significantly reverse this neurite outgrowth deficit (Fig-
ures S3A and S3B). Also, overexpression of Hsc70 via adenoviral
vector in the cerebellum of KI mice reduced the degeneration of
Purkinje cells and increased the levels of MANF in Purkinje cells
(Figures S3C and S3D). Altogether, these findings suggest that
chaperone activity is critical for maintaining the normal function
of mutant TBP and that the age-dependent decrease in its
activity leads mutant TBP to lose its normal function and alters
gene expression important for neuronal survival.
MANF Overexpression Ameliorates Mutant TBP Toxicity
In Vitro and In Vivo
If a decreased MANF level in the cerebellum contributes to Pur-
kinje cell degeneration in SCA17 mice, then overexpression of
MANF should alleviate this pathological change. To test this
hypothesis, we generated a lentiviral MANF vector in which
mouse MANF is linked with ECFP through an F2A sequence
and is expressed under the control of the ubiquitin promoter (Fig-
ure 7A). When translated, the F2A peptide can be self-cleaved in
order to separate MANF and ECFP, and ECFP fluorescence
could be an indicator of MANF expression. First, we infected
HEK293 cells with MANF lentivirus and detected robust expres-
sion of both MANF and ECFP via western blotting (Figure 7B).
Then, we infected stable PC12 cell lines that express either
TBP13Q or TBP105Q. After NGF stimulation, we found that
MANF overexpression could significantly increase the numbers
of TBP105Q cells containing long neurites versus control cells
(Figures 7C and 7D), which suggests that MANF rescues the
neurite outgrowth defect caused by mutant TBP. The PC12 cells
expressing mutant TBP are also sensitive to apoptotic stimuli,
such as staurosporine treatment (Shah et al., 2009). MTS assay
showed that MANF overexpression was able to significantly
improve the survival of TBP105Q PC12 cells (Figures 7E and 7F).
Next, we performed stereotaxic injection of lentivirus express-
ing MANF into the cerebellum of 12-month-old TBP105Q induc-
ible KI mice. MANF lentivirus was injected on the right side of the
cerebellum, and the lentivirus expressing GFP alone was in-
jected into the left side as a control. The injected mice were sub-
jected to tamoxifen treatment 1 month later in order to express
mutant TBP for another 1.5 months before being examined.
Immunofluorescence staining of the cerebellum revealed the
expression of ECFP and GFP, which was used to locate the
site of virus infection, and calbindin staining was used to visu-
alize Purkinje cells (Figure 7G). In WT mice, both lentiviral
MANF- and GFP-infected sides showed a comparable density
of Purkinje neurons (Figure 7G). However, in the KI cerebellum,(D) The relative amounts of TBP precipitated with XBP1s (*p < 0.05).
(E) Schematic map of luciferase constructs for reporter assay. Luciferase activ
increased luciferase intensity.
(F) Western blotting verifying the coexpression of TBP, Hsc70, and XBP1s with t
(G) Overexpression of Hsc70 significantly rescued the impaired luciferase activit
(H) Western blot analysis of MANF expression levels in TBP stably transfected ce
MANF to actin on the blot are also presented (*p < 0.05). Data are represented awe saw a severe loss of Purkinje neurons caused by mutant
TBP in the lentiviral GFP-infected side, and, importantly, the
lentiviral MANF-infected side had a significant increase in the
number of Purkinje neurons (Figures 7G and 7H), further con-
firming the protective effect of MANF on mutant TBP toxicity.
Transgenic MANF Expression Alleviates Ataxic Gait and
Purkinje Cell Neurodegeneration in SCA17 KI Mice
through PKC Signaling Pathway
Injected MANF lentivirus can only infect a limited area of the
cerebellum; therefore, it was difficult to see behavioral changes
of SCA17 mice after injection. We generated a MANF transgenic
mouse model in which the prion promoter was used to drive the
expression of MANF that is tagged with human influenza hemag-
glutinin (HA) at the C terminus (Figure 8A). Western blot (Fig-
ure 8B) and immunohistochemistry (Figure S4) with anti-HA tag
confirmed that transgenic MANF was widely expressed in the
brain of transgenic mice. Using TBP105Q loxPmice, we recently
obtained KI mice (SCA17 KI) that expressed mutant TBP105Q
from germline and displayed ataxic gait, manifested by signifi-
cantly shorter strides and poor coordination between forepaws
and hindpaws at the age of 6 months. We crossed MANF trans-
genic mice with these SCA17 KI mice and generated KI/MANF
mice that express both mutant TBP and transgenic MANF. At
6 months of age, KI/MANF mice showed significant improve-
ment in foot-printing phenotype (Figure 8C) and clasping pheno-
types (Figures S5A and S5B) in comparison to SCA17 KI mice.
Quantification of stride lengths in the foot-printing assay and
walking time during the balance beam test verified a significant
improvement of motor function and coordination of KI/MANF
mice (Figure 8D). Western blotting results revealed an upregula-
tion of calbindin levels in the SCA17 KI mouse cerebellum ex-
pressing transgenic MANF (Figure 8E). In agreement with this
result, immunofluorescent staining showed that transgenic
MANF was also protective on Purkinje neuron survival, given
that a significantly higher density of Purkinje neurons was seen
in the cerebellum of KI/MANF mice in comparison to SCA17 KI
mice (Figure 8F). In addition, the thickness of molecular layer
and dendritic complexity was also improved in KI/MANF mice
(Figures 8G and S5C). It should be noted that a similar amount
of mutant TBP was seen in both SCA17 KI and KI/MANF mice
(Figure 8E), suggesting that the rescue effect of MANF was not
due to a reduced level of mutant TBP but resulted from
improving MANF function.
MANF is found to have neurotrophic effects for rescuing
apoptotic neurons (Hellman et al., 2011). Using immunostaining
with an antibody to activated caspase 3, we found a minimal
level of activated caspase 3 in the cerebellum of SCA17 KI and
KI/MANF mice (Figure S6), indicating that the primary cause of
Purkinje neuron degeneration in SCA17 is not apoptosis. Givenity of transfected HEK293 cells showed that XBP1s, but not XBP1u, greatly
he MANF promoter reporter.
y by TBP105Q (*p < 0.05).
lls that were transfected with (+) or without (–) HA-tagged Hsc70. The ratios of
s mean ± SEM.
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MANF Decrease and Selective Neuropathology in SCA17that MANF can also bind membrane receptors in order to trigger
intracellular signaling (Henderson et al., 2013), we produced
His-tagged MANF in bacteria and purified this recombinant pro-
tein (Figure 8H), which was then applied to cultured PC12 cells
(1.5 mg/ml) in order to identify intracellular signaling event that
is likely to associate with the neuronal protective effect of
MANF. Using antibodies to phosphorylated signaling proteins,
we found that protein kinase C phosphorylation was increased
byMANF (Figure 8I). Western blotting and immunohistochemical
assays also showed a significant reduction in PKC phosphoryla-
tion in SCA17 KI mouse cerebellum tissue (Figures 8J and S7A).
However, this reduction could be attenuated by the expression
of transgenic MANF (Figure 8J).
It has also been reported that prolonged treatment with PMA,
a PKC modulator, could reduce PKC expression and phosphor-
ylation (Freisewinkel et al., 1991; Ohigashi et al., 1999). We intra-
peritoneally injected PMA into 3-month-old WT and SCA17 KI
mice (0.15 mg/kg, once every 3 days) for 24 days and found
that this prolonged treatment indeed reduced phosphorylation
of PKC (Figure S7B) and could worsen the motor impairment
of SCA17 KI mice (Figure S7C). Reduction in PKC signaling
has recently been found to affect dendritic branches and
morphology of cerebellar Purkinje cells in the mouse brain (Tho-
manetz et al., 2013). It would be interesting to see whether the
overexpression of PKC is able to reduce Purkinje cell pathology
in SCA17 mice. Thus, we injected adenoviral vector expressing
PKCg into the cerebellum of SCA17 KI mice at 5 months of
age. We observed a significant increase in the number of
Purkinje cells and dendritic branches in the injected cerebellum
of SCA17 KI mice 3 weeks after injection (Figures 8K, 8L, and
S7D). These findings identified PKC as a downstream compo-
nent of MANF-mediated signaling pathway and also highlighted
the importance of PKC phosphorylation on the survival of adult
Purkinje cells in SCA17.
DISCUSSION
Although aging is a primary risk factor promoting neurodegener-
ation caused by misfolded proteins, differentiating the cumula-
tive effects of misfolded proteins on neurons over time versus
aging-related factors that may make neurons vulnerable to mis-
folded proteins has proved difficult. Using our inducible SCA17
mouse model, we provide convincing evidence that aged
neuronal cells are more vulnerable to misfolded proteins andFigure 7. Overexpression of MANF Ameliorates Toxicity Caused by Mu
(A) Schematic map of lentiviral MANF vector.
(B) Western blotting analysis of HEK293 cells infected with lentiviral MANF for two
HEK293 cells (Con) were used as a negative control.
(C and D) PC12 cells stably expressing either WT TBP (TBP13Q) or mutant TBP (T
(C) and quantitative analysis (D; n = 15, **p < 0.01) showed that MANF signi
represents 10 mm.
(E) Western blot analysis of PC12 cells stably expressing either WT TBP (TBP13Q
(F) MTS assay showed a significant increase in the survival of PC12 cells (versu
lentiviral MANF in comparison to lentiviral GFP (*p < 0.05, **p < 0.01).
(G) One-year-oldWT and TBP105Q inducible KI mice were injected withMANF len
Fluorescence of GFP or ECFP was used to locate the region infected by lentivir
Purkinje neurons caused by mutant TBP. The scale bar represents 50 mm.
(H) Quantitative assessment of the number of Purkinje cells labeled by anticalbindthat this vulnerability is related to the age-dependent decline in
chaperone activity. Furthermore, we found that mutant TBP
affects MANF expression and PKC signaling in Purkinje cells,
which suggests a different pathogenic pathway in SCA17.
Strong evidence for the above idea comes from TBP105Q
inducible KI mice expressing mutant TBP at the endogenous
level for the same length of time: it is older KI mice that develop
earlier and more progressive neurological phenotypes as well as
more severe degeneration of cerebellar Purkinje neurons. How-
ever, the protein levels are determined not only by the time of
synthesis but also by degradation. We found that more soluble
mutant TBP was present in older KI mouse brains than the
younger KI mouse brains, suggesting that mutant TBP is more
stable in older neurons. A decreased cellular capacity to clear
misfolded proteins by the UPS is seen in different brain regions
and different types of cells (Keller et al., 2000), which could
account for the increased levels of mutant proteins. However,
this increased level is unlikely to be the sole determinant of selec-
tive neurodegeneration, given that mutant TBP is increased to a
greater degree in the cortex than in the cerebellum, whereas it
causes degeneration of Purkinje cells in the cerebellum. Thus,
other cell-type-specific and aging-related factors must be
involved in the selective neurodegeneration.
We identified MANF as a cell-type-specific target for Purkinje
cell degeneration in SCA17.MANF is a newly discovered, nonca-
nonical neurotrophic factor. Unlike other classical neurotrophins,
such as NGF, BDNF, and NT-3, whichmainly function by binding
to their respective receptors in the cell membrane, MANF is
believed to exert its neuroprotective effects both extracellularly,
through binding to a currently unidentified receptor (Voutilainen
et al., 2009), and intracellularly, by inhibiting apoptosis (Hellman
et al., 2011). We provide several lines of evidence to support the
idea that MANF is involved in the selective Purkinje cell degener-
ation in SCA17. First, MANF is enriched in Purkinje cells, and its
expression is reduced in SCA17 mouse cerebellum. Second, as
a neuronal protective factor, the overexpression of MANF can
alleviate Purkinje cell degeneration in SCA17 KI mouse brains.
Third, the expansion of polyQ repeats reduces TBP binding to
XBP1s and decreases the association of XBP1s to the promoter
of MANF, resulting in decreased expression of MANF. Finally, we
found that MANF could increase PKC phosphorylation in the
cerebellum of SCA17 mice. Because TBP level is strictly regu-
lated and the increased levels of mutant TBP can reduce the
level of normal TBP, both the lower level of normal TBP andtant TBP In Vitro and In Vivo
days (Infected) confirming the expression of both MANF and ECFP. Uninfected
BP105Q) were infected with lentiviral MANF or uninfected. Fluorescent imaging
ficantly increased the percentage of cells with long neurites. The scale bar
) or mutant TBP (TBP105Q), which were infected with lentiviral MANF or GFP.
s non-staurosporine-treated cells) expressing mutant TBP when infected with
tivirus on the right side of the cerebellum andwith lentiviral GFP on the left side.
us. Calbindin staining showed that MANF overexpression rescued the loss of
in per image field (203, n = 9, *p < 0.05). Data are represented as mean ± SEM.
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Figure 8. Expression of Transgenic MANF Ameliorates Pathological Phenotypes of SCA17 KI Mice via PKC Phosphorylation
(A) Schematic map of transgenic MANF construct.
(B) Anti-HA western blotting verified the expression of transgenic MANF-HA in the brain cortex and cerebellum in MANF transgenic mouse.
(C) Gait of SCA17 KI and KI/MANF mice was assessed with foot-printing assay.
(legend continued on next page)
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MANF Decrease and Selective Neuropathology in SCA17the dysfunction of mutant TBP can contribute to the decreased
level of MANF via a similar mechanism of loss of function
reported in other polyQ diseases (Lim et al., 2008; Nedelsky
et al., 2010), resulting in impaired function of MANF in neuronal
cells.
The signaling pathways mediated by MANF remain largely
unclear. Using recombined MANF in PC12 cells, we found that
MANF increased PKC phosphorylation. This finding led us to
uncover the significant reduction of PKC phosphorylation in
the cerebellum in SCA17 KI mice. Importantly, transgenic
MANF can alleviate the reduction in PKC phosphorylation in
SCA17 KI mouse cerebellum. Several studies indicate that
PKC activity modulates Purkinje cell maturation, and reduction
or absence of PKC signaling leads to abnormal Purkinje cell den-
dritic morphology and dysfunction during early development
(Gundlfinger et al., 2003; Metzger and Kapfhammer, 2003;
Thomanetz et al., 2013). PKC has complex effects, which are
cell-type-dependent and different in developing neurons and
adult neurons. It would be more important to understand
whether and how PKC function is involved in the survival of
Purkinje neurons in adult mice, given that SCA17 neuropa-
thology occurs in adult neurons and that loss of PKC signaling
has been found in the Purkinje cells of SCA1 mouse model
(Skinner et al., 2001). In addition, PKCg-null mice displayed
impaired motor coordination (Chen et al., 1995). The importance
of studying the role of PKC in adult neurons is also underscored
by the fact that mutations in PKCg can cause spinocerebellar
ataxia 14, another age-dependent ataxia disease that is also
characterized by cerebellar Purkinje cell degeneration (Chen
et al., 2003; Shuvaev et al., 2011). Thus, decreased PKC activity
mediated by loss of MANF could contribute to the late onset of
Purkinje cell degeneration in SCA17.
Another important finding in our study is that an age-
dependent decrease in Hsc70 contributes to age-dependent
and selective neurodegeneration. Hsc70 is a constitutively ex-
pressed chaperone, which is different from other stress-induced
chaperones, such as Hsp70 and Hsp40. Although both constitu-
tive and inducible types of chaperones are thought to have
similar effects on protein refolding and protection against
neuronal damage, how they are related to the aging-related neu-
rodegeneration process remains unclear. We found that Hsc70,(D) KI/MANFmice show longer stride lengths in foot-printing test and shorter walki
in gait performance and motor coordination (n = 6 each group, *p < 0.05).
(E)Western blotting analysis ofmutant TBP labeled by 1C2 antibody, transgenicM
KI and KI/MANF mice. Actin was used as a loading control. The ratio of calbindi
(F) Immunofluorescent staining images (103 by confocal microscope) of SCA1
Purkinje neurons, and HA antibody was used to stain transgenic MANF. The sca
(G) Quantitative assessment of the number of Purkinje neurons labeled by anticalb
n = 9, *p < 0.05, **p < 0.01).
(H) Coomassie staining of SDS gel containing total bacterial lysates and eluted H
(I) The purified His-MANF was applied to PC12 cells, and the PC12 cell lysates w
western blotting with an antibody to phosphor-PKC (pPKC). Actin was used as a
(*p < 0.05).
(J) Western blotting analysis of pPKC and PKCg in the cerebellum of mice with d
(*p < 0.05, **p < 0.01).
(K) Immunofluorescent staining images of Purkinje neuron of SCA17 KI cerebellum
reveal Purkinje neurons, and PKCg antibody was used to detect viral PKCg. The
(L) Quantitative analysis of the number of Purkinje cells and their branches in K
represented as mean ± SEM.but not Hsp40 or Hsp70, is selectively reduced in the brain with
age. When a cell ages, senescing signals arise, typically as a
result of DNA damage due to oxidative stress or telomere short-
ening. Regulation of the expression of constitutive chaperones
may be more sensitive to aging-related oxidative damage than
other inducible chaperones. The selective decrease of Hsc70
we see in the aged brain suggests that aging is more likely to
affect the chaperoning function of unstressed neurons, which
fits well with the slow and progressive decline of cellular function
for coping with misfolded proteins in the aged brains.
Hsc70 is also known to be involved in chaperone-mediated
autophagy (CMA) by targeting proteins to lysosomes (Chiang
et al., 1989). However, CMA activity is preserved in mice up to
12 months of age and could be upregulated by mutant polyQ
proteins (Koga et al., 2011), so the decreased CMA function is
unlikely to be involved in the neurotoxicity of mutant TBP in
SCA17 KI mice younger than 12 months. In addition, mutant
TBP is a nuclear protein whose turnover is unlikely to depend
on the cytoplasmic CMA. Like other chaperones, Hsc70’s critical
function is to maintain protein folding and prevent their abnormal
conformation and dysfunction or toxicity. Hsc70 is found to
interact with cochaperones in order tomaintain the conformation
and interactions of protein complexes, such as DNA binding pro-
tein complex (Gehring, 2004; Li et al., 2008; Zeiner et al., 1999).
Indeed, we found that the overexpression of Hsc70 can improve
the association of mutant TBPwith XBP1s and increase the tran-
scription activity of the MANF promoter. Thus, a lower level of
Hsc70 may impair the function of mutant TBP on the expression
of MANF. Because MANF is enriched in Purkinje cells, this
decrease can affect Purkinje cells in particular and contributes
to the selective neurodegeneration in SCA17.
Our findings may have broad therapeutic implications for age-
dependent neurodegenerative diseases. The effect of Hsc70 on
mutant TBP’s association with MANF suggests that improving
this chaperone function can still effectively reduce mutant pro-
tein toxicity, even when mutant proteins have accumulated.
Furthermore, we identified MANF as an additional target and
PKC phosphorylation as its downstream signaling for SCA17
therapy. Because decreased levels in chaperone and MANF
occur in old neurons, their function can be improved in the old
age, which would be more economical than other preventativeng time in balance beam assay than SCA17 KI mice, indicating an improvement
ANF labeled by anti-HA, and calbindin in the cerebellum of 6-month-old SCA17
n to actin is presented under the gel data (*p < 0.05).
7 KI and KI/MANF mouse cerebellum. Calbindin staining was used to reveal
le bar represents 50 mm.
indin per image field, dendritic branches, and thickness ofmolecular layer (103,
is-MANF (arrowhead).
ere collected 1, 2, 5, 10, and 20 min after MANF treatment and subjected to
loading control. The ratios of pPKC to actin are shown beneath the gel image
ifferent genotypes. The ratios of pPKC to actin are show under the gel image
injectedwith (+) or without (–) PKCg adenovirus. Calbindin staining was used to
scale bar represents 50 mm.
I mice injected with or without viral PKCg (203, n = 9, *p < 0.05). Data are
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MANF Decrease and Selective Neuropathology in SCA17therapeutics that need to begin in earlier life. Given that Purkinje
neuron degeneration is also prominent in other types of SCA dis-
eases, the identification of MANF provides a potential target for
the treatment of specific neurodegeneration in these diseases.
EXPERIMENTAL PROCEDURES
Antibodies and Plasmids
Antibodies and plasmids are described in the Supplemental Information.
Mouse Lines and Tamoxifen Injection
All mice were bred and maintained in the animal facility at Emory University
under specific pathogen-free conditions in accordance with institutional
guidelines of the Animal Care and Use Committee at Emory University. The
TBP105Q floxed mice were generated as described previously (Huang et al.,
2011). To generate TBP105Q inducible KI mice, we crossed heterozygous
floxed TBP105Q mice with CreER transgenic mice (the Jackson Laboratory,
B6.Cg-Tg[CAG-cre/Esr1]5Amc/J) that express tamoxifen-inducible Cre
throughout the body. To generate germ-line KI (SCA17 KI) mice, we crossed
heterozygous TBP105Q floxed mice with EIIa-Cre transgenic mice (the Jack-
son Laboratory, B6.FVB-Tg [EIIa-Cre] C5379Lmgd/J) in which Cre transgene
under the control of the adenovirus EIIa promoter is expressed in germline cells
that transmit the genetic alteration to progeny. Primers were used for genotyp-
ing of the presence of mutant TBP (forward, 50-CCA CAG CCT ATT CAG AAC
ACC-30; reverse, 50-AGA AGC TGG TGT GGC AGG AGT GAT-30) and Cre (for-
ward, 50-GCG GTC TGG CAG TAA AAA CTA TC-30; reverse, 50-TGT TTC ACT
ATC CAG GTT ACG G-30 ). To generate MANF transgenic mice, we inserted
MANF cDNA linked with HA sequence into a previously described vector con-
taining prion promoter (Friedman et al., 2007). The vector was sent to the
Transgenic Mouse & Gene Targeting Core at Emory University for microinjec-
tion. Primers used for genotyping of transgenic MANF were forward, 50-ATT
GAC CTG AGC ACA GTG GAC CTG-30; reverse, 50-GTC ACT GTC ACC TTG
TAC TCT GG-30.
For the injection of tamoxifen into the mice, tamoxifen (Sigma-Aldrich,
T5648) was dissolved in 100% ethanol to 10 mg/ml; corn oil (Sigma-Aldrich,
C8267) was added and mixed thoroughly before ethanol was evaporated
with Vacufuge plus (Eppendorf). Tamoxifen, dissolved in corn oil, was injected
intraperitoneally into mice at 0.1 mg per 1 g body weight for 5 consecutive
days.
For injection of Phorbol 12-myristate 13-acetate (PMA) into the mice, PMA
(Sigma-Aldrich, P8139) was dissolved in corn oil and injected intraperitoneally
into mice at the dose of 0.15 mg per 1 kg body weight every 3 days.
Mouse Behavior Tests
Mouse behavior tests were performed as described previously (Huang et al.,
2011). Detailed procedures are provided in the Supplemental Information.
Cell Culture
Cell culture was performed as described previously (Shah et al., 2009). See
also the Supplemental Information.
Viral Vector, Stereotaxic Injection, and Quantification of Neuronal
Degeneration
Detailed procedures are described in the Supplemental Information.
Western Blot, Immunohistochemistry, and Immunoprecipitation
Methods were described previously (Huang et al., 2011). See also the
Supplemental Information.
Luciferase Protection Assay
Assays were performed as described previously (Thulasiraman and Matts,
1998) with modifications (see the Supplemental Information).
RNA Expression and Promoter Transcriptional Activity Assay
Assays were performed as described previously (Friedman et al., 2007. See
also the Supplemental Information.364 Neuron 81, 349–365, January 22, 2014 ª2014 Elsevier Inc.Purification of Recombinant MANF Protein
This procedure is described in the Supplemental Information.
Statistical Analysis
For mouse behavioral analysis, each group consisted of at least six animals.
For western blot analysis, immunostaining, or other biochemical assays,
data were generated from three or more experiments, and the results were
expressed as mean ± SEM. Statistical significances were calculated on the
basis of a Student’s t test, one-way ANOVA or two-way ANOVA, or a chi-
square test. A p value < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.neuron.2013.12.002.
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